Literature DB >> 15831268

Epidemiology of hepatocellular carcinoma.

F Xavier Bosch1, Josepa Ribes, Ramon Cléries, Mireia Díaz.   

Abstract

Year 2000 estimates of the incidence of cancer indicate that primary liver cancer remains the fifth most common malignancy in men and the eighth in women. The number of new cases has been predicted as 564,000, corresponding to 398,000 in men and 166,000 in women. The geographic areas at highest risk are located in Eastern Asia, Middle Africa, and some countries of Western Africa. Changes in incidence among migrant populations underline the predominant role of environmental factors in the etiology of primary liver cancer. In high-risk countries, the early cases of primary liver cancer occur already at ages 20 and above, underlying the impact of viral exposures early in life. In countries at low risk, primary liver cancer is rare before the 50s, translating the impact of late exposures with moderate risks and long latency intervals. Sex ratios are typically between 2 and 4. The incidence of primary liver cancer is increasing in several developed countries including the United States, and the increase will likely continue for several decades. The trend has a dominant cohort effect related to exposures to hepatitis B and C viruses. The variability of primary liver cancer incidence is largely explained by the distribution and the natural history of the hepatitis B and C viruses. The attributable risk estimates for the combined effects of these infections account for well over 80% of liver cancer cases worldwide. Primary liver cancer is the first human cancer largely amenable to prevention using hepatitis B virus vaccines and screening of blood and blood products for hepatitis B and C viruses.

Entities:  

Mesh:

Year:  2005        PMID: 15831268     DOI: 10.1016/j.cld.2004.12.009

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  253 in total

1.  Non-alcoholic fatty liver disease: is iron relevant?

Authors:  Julia O'Brien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2011-08-12       Impact factor: 6.047

2.  CCL5-28, CCL5-403, and CCR5 genetic polymorphisms and their synergic effect with alcohol and tobacco consumptions increase susceptibility to hepatocellular carcinoma.

Authors:  Hsiu-Ting Tsai; Shun-Fa Yang; Dar-Ren Chen; Szu-Erh Chan
Journal:  Med Oncol       Date:  2012-02-29       Impact factor: 3.064

Review 3.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

Review 4.  Serum markers of hepatocellular carcinoma.

Authors:  Giulia Malaguarnera; Maria Giordano; Isabella Paladina; Massimiliano Berretta; Alessandro Cappellani; Mariano Malaguarnera
Journal:  Dig Dis Sci       Date:  2010-03-26       Impact factor: 3.199

5.  Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury.

Authors:  Nikhil Bhagat; Diane K Reyes; Mingde Lin; Ihab Kamel; Timothy M Pawlik; Constantine Frangakis; J F Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2012-06-22       Impact factor: 2.740

6.  High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma.

Authors:  Wei Jiang; Zhiming Wang; Xinying Li; Xuegong Fan; Yankun Duan
Journal:  Pathol Oncol Res       Date:  2011-09-07       Impact factor: 3.201

7.  A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma.

Authors:  Nabil Mohie Abdel-Hamid; M M Abouzied; M H Nazmy; M A Fawzy; A S Gerges
Journal:  Tumour Biol       Date:  2015-09-19

8.  Interleukin-6 mediates G(0)/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway.

Authors:  Dairmuid M Moran; M Adrian Mattocks; Paul A Cahill; Leonidas G Koniaris; Iain H McKillop
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

9.  Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Alessandro Valdegamberi; Silvia Pachera; Tommaso Campagnaro; Mirko D'Onofrio; Enrico Martone; Paola Nicoli; Calogero Iacono
Journal:  J Gastrointest Surg       Date:  2007-11-13       Impact factor: 3.452

10.  Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.

Authors:  Charlotte E Edling; Federico Selvaggi; Ragheda Ghonaim; Tania Maffucci; Marco Falasca
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.